VYGR - NASDAQ
Voyager Therapeutics, Inc.
$3.62
+1.7%Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live Snapshotvygr
Property, Plant, and Equipment (Net)
Last Annual Value
41.61M
3-Year CAGR
8%
5-Year CAGR
-8%
10-Year CAGR
29%
Voyager Therapeutics, Inc. Competitors Analysis of Property, Plant, and Equipment (Net)
| Company | Property, Plant, and Equipment (Net) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Voyager Therapeutics, Inc. NASDAQ:VYGR | 41.61M | 11.5% | -5.6% | 18.1% | |
 Entrada Therapeutics, Inc. NASDAQ:TRDA | 67.76M | -9.9% | 61.0% | N/A | |
 Sagimet Biosciences Inc. NASDAQ:SGMT | 78.00K | 2.2% | -25.6% | N/A | |
 Atea Pharmaceuticals, Inc. NASDAQ:AVIR | 1.09M | -29.5% | 42.8% | N/A | |
 Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | 72.94M | 28.1% | 46.9% | 24.7% | |
 Humacyte, Inc. NASDAQ:HUMA | 47.69M | 2.6% | -3.6% | N/A | |
 Alector, Inc. NASDAQ:ALEC | 24.55M | -19.5% | -15.8% | 25.5% | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 5.42M | -20.1% | -7.0% | N/A | |
 Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | 8.86M | -10.3% | 119.5% | N/A | |
 Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | 457.00K | -59.5% | -35.3% | N/A | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 10.28M | -5.7% | 109.6% | N/A |
Voyager Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your VYGR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.